Classification Systems of Endometrial Cancer: A Comparative Study about Old and New

Area of Science:

• Gynecology
• Oncology
• Genomics

Background:

• Endometrial cancer, a common gynecological malignancy, was historically classified into type I and type II.
• The Cancer Genome Atlas (TCGA) proposed a molecular classification in 2013, refining diagnostic approaches.
• Accurate classification is crucial for predicting prognosis and guiding treatment strategies.

Purpose of the Study:

• To compare the predictive power of different endometrial cancer classification systems on a patient cohort.
• To identify the most effective classification scheme for risk stratification in endometrial cancer.
• To determine key prognostic factors influencing patient outcomes.

Main Methods:

• Retrospective analysis of 117 endometrial cancer patients.
• Collection of clinical parameters including age, BMI, stage, menopause status, and tumor characteristics.
• Classification of tumors using European Society for Medical Oncology (ESMO), Proactive Molecular Risk Classifier (PMRC), Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC), and TCGA schemes.

Main Results:

• The ESMO classification was confirmed as the strongest predictor of prognosis within the study cohort.
• Histotype, FIGO stage, and tumor grade were significantly correlated with poor prognosis.
• The study demonstrated the utility of integrating histologic, clinical, and molecular parameters for risk stratification.

Conclusions:

• The European Society for Medical Oncology (ESMO) risk classification system provides superior prognostic prediction for endometrial cancer.
• Accurate risk stratification requires a comprehensive approach, integrating histological, clinical, and molecular data.
• Further research should focus on validating and refining integrated models for personalized endometrial cancer management.